Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Telmisartan Does Not Significantly Reduce Risk of Recurrent Stroke, Cardiovascular Events - (DGNews)
    Percutaneous Coronary Intervention Not Inferior to Bypass Grafting in Diabetic Patients With Multivessel Disease: Presented at ESC - (DGDispatch)
    Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis - (BMJ)
    TopAbstracts in Diabetes 09/02/2008 - (DGNews)
    Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events - (N Engl J Med)

    News archive

     Recent webcasts/CME - Diabetes
      Cardiometabolic Risk and Risk Management
      An Evolving Approach to the Treatment of Type 2 Diabetes
      Obesity, Type 2 Diabetes, and Cardiovascular Disease
      Global Perspectives on Diabetic Retinopathy: More Than Meets the Eye
      Type 1 Diabetes - New Insights into Pathophysiology, Treatment, and the Search for a Cure

      Webcasts/CME archive

       Recent cases - Diabetes
        Diabetic Fetopathy Associated with Bilateral Adrenal Hyperplasia and Ambiguous Genitalia: A Case Report
        Somatostatinoma: A Rare Cause of Diabetic Ketosis
        New Onset Diabetes Complicated by Haemolysis and Rhabdomyolysis: A Case Report and Review of the Literature
        Diabetic Control and Atypical Antipsychotics: A Case Report
        Treatment with Pioglitazone Induced Significant, Reversible Mitral Regurgitation

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Sildenafil Treatment Less Effective in Men With Diabetes Than in Non-Diabetics

        A DGReview of :"Oral sildenafil in the treatment of erectile dysfunction in diabetic men; A randomized double-blind and placebo-controlled study"
        Journal of Diabetes and its Complications

        07/09/2004
        By Shane Alexander


        Oral sildenafil is only moderately effective in the treatment of erectile dysfunction in patients with diabetes, an Iranian researcher reports.

        "The response rate was lower and cardiovascular events were higher than previously reported in nondiabetic patients," writes M. R. Safarinejad, MD, Department of Urology, Military University of Medical Sciences, Tehran.

        A total of 282 men (mean age 46.4 years) with erectile dysfunction (mean duration 3.6 years) and diabetes (mean duration 11 years) were recruited for this randomised, double-blind, placebo-controlled trial.

        Over the 16-week study period, 144 men were assigned to receive sildenafil 100 mg approximately 1 hour before sexual activity and 138 men received a matching placebo.

        Treatment efficacy was evaluated using the International Index of Erectile Function questionnaire. Ninety-three percent of men in the sildenafil group and 93% of men in the placebo group completed the study.

        The investigator reports positive clinical results in 51% of men in the sildenafil group compared with 11% of men in the placebo group (P < .003). In the sildenafil group, 59% of men noted at least 1 successful attempt at sexual intercourse compared with 21% of men in the placebo group (P < .002).

        Adverse effects were reported by 22 % of men treated with sildenafil compared with 3 % of men in the placebo group. The most frequently reported adverse events were: headaches (sildenafil: 20%, placebo: 2%), flushing (sildenafil: 19%, placebo: 0%), rhinitis (sildenafil: 6%, placebo: 0%), and cardiovascular events (sildenafil: 7%, placebo: 0%).

        Two percent of patients treated with sildenafil reported new chest pain; myocardial infarction was documented in half of those patients.

        J Diabetes Complications 2004 Jul-Aug;18:4:205-10 "Oral sildenafil in the treatment of erectile dysfunction in diabetic men; A randomized double-blind and placebo-controlled study"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send